Bristol-Myers Squibb Co. [BMY] stock is trading at $50.45, up 11.44%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The BMY shares have gain 18.32% over the last week, with a monthly amount glided 18.71%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Bristol-Myers Squibb Co. [NYSE: BMY] stock has seen the most recent analyst activity on March 11, 2024, when Societe Generale downgraded its rating to a Hold. Previously, Redburn Atlantic downgraded its rating to Neutral on February 06, 2024, and dropped its price target to $54. On January 03, 2024, downgrade downgraded it’s rating to Neutral and revised its price target to $60 on the stock. Cantor Fitzgerald downgraded its rating to a Neutral and decreased its price target to $55 on November 15, 2023. Deutsche Bank initiated its recommendation with a Hold and recommended $55 as its price target on November 09, 2023. Daiwa Securities downgraded its rating to Neutral for this stock on November 02, 2023, and downed its price target to $54. In a note dated October 27, 2023, HSBC Securities upgraded an Hold rating on this stock and revised its target price from $55 to $53.
Bristol-Myers Squibb Co. [BMY] stock has fluctuated between $39.35 and $63.89 over the past year. Currently, Wall Street analysts expect the stock to reach $68.15 within the next 12 months. Bristol-Myers Squibb Co. [NYSE: BMY] shares were valued at $50.45 at the most recent close of the market. An investor can expect a potential return of 35.08% based on the average BMY price forecast.
Analyzing the BMY fundamentals
Bristol-Myers Squibb Co. [NYSE:BMY] reported sales of 46.51B for the trailing twelve months, which represents a growth of 8.69%. Gross Profit Margin for this corporation currently stands at 0.71% with Operating Profit Margin at 0.27%, Pretax Profit Margin comes in at -0.14%, and Net Profit Margin reading is -0.14%. To continue investigating profitability, this company’s Return on Assets is posted at -0.07, Equity is -0.28 and Total Capital is 0.17. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 3.09.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 48.58 points at the first support level, and at 46.72 for the second support level. However, for the 1st resistance point, the stock is sitting at 51.46, and for the 2nd resistance point, it is at 52.48.
Ratios To Look Out For
For context, Bristol-Myers Squibb Co.’s Current Ratio is 1.16. As well, the Quick Ratio is 1.02, while the Cash Ratio is 0.27. Considering the valuation of this stock, the price to sales ratio is 2.20, the price to book ratio is 6.01.
Transactions by insiders
Recent insider trading involved BOERNER CHRISTOPHER S., Chief Executive Officer, that happened on Dec 05 ’23 when 2000.0 shares were purchased. Chief Executive Officer, BOERNER CHRISTOPHER S. completed a deal on Nov 28 ’23 to buy 3071.0 shares. Meanwhile, Director Samuels Theodore R. II bought 8500.0 shares on Nov 20 ’23.
